Howard Capital Management’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.04M Sell
21,447
-42
-0.2% -$16.7K 0.11% 63
2026
Q2
$7.78M Buy
21,489
+10,021
+87% +$3.43M 0.09% 75
2026
Q1
$4.04M Sell
11,468
-9,883
-46% -$3.52M 0.07% 85
2025
Q4
$6.99M Buy
21,351
+383
+2% +$121K 0.09% 67
2025
Q3
$5.92M Sell
20,968
-8
-0% -$2.32K 0.08% 72
2025
Q2
$5.86M Buy
20,976
+3,060
+17% +$867K 0.09% 63
2025
Q1
$5.58M Sell
17,916
-2,099
-10% -$620K 0.14% 49
2024
Q4
$5.22M Buy
20,015
+468
+2% +$139K 0.08% 60
2024
Q3
$6.3M Buy
+19,547
New +$6.39M 0.1% 47
2023
Q3
– Sell
-11,148
Closed -$2.48M – 57
2023
Q2
$2.48M Buy
11,148
+1,132
+11% +$263K 0.33% 24
2023
Q1
$2.42M Buy
+10,016
New +$2.46M 0.42% 17
2018
Q4
– Sell
-57,626
Closed -$12M – 16
2018
Q3
$12M Buy
57,626
+35
+0.1% +$6.9K 1.16% 26
2018
Q2
$11.2M Sell
57,591
-49,725
-46% -$8.8M 1.22% 15
2018
Q1
$18.3M Buy
107,316
+65,377
+156% +$12M 2.31% 9
2017
Q4
$7.29M Hold
41,939
– – 1.16% 55

Other funds holding AMGN

Howard Capital Management's AMGN Position: Q3 2026 in Review

Howard Capital Management reduced its Amgen (AMGN) stake by 0.2% in Q3 2026, selling an estimated $16.7K and leaving 21,447 shares worth $9.04M. The position accounts for 0.11% of the portfolio, ranked #63.

Howard Capital Management first reported a position in AMGN in Q4 2017 and has held it in 15 quarters since. The position peaked at $18.3M in Q1 2018. 3,275 funds tracked by Wall St. Rank hold AMGN as of Q3 2026.

  • Howard Capital Management held 21,447 shares of Amgen worth $9.04M as of Q3 2026.
  • Howard Capital Management sold 42 Amgen shares in Q3 2026, an estimated $16.7K.
  • Amgen made up 0.11% of Howard Capital Management's portfolio in Q3 2026, its #63 holding.
  • Howard Capital Management first reported a position in Amgen in Q4 2017 and has held it in 15 quarters since.
  • Howard Capital Management's Amgen position peaked at $18.3M in Q1 2018.
  • 3,275 funds tracked by Wall St. Rank held Amgen as of Q3 2026.

Based on Howard Capital Management's 13F filing for Q3 2026, filed 16 Oct 2026.